Relapsed T cell Non-Hodgkin Lymphoma
Showing 1 - 25 of >10,000
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)
Recruiting
- B-Cell Non Hodgkin Lymphoma
- B-Cell Acute Lymphoblastic Leukemia
- anti-CD19 CAR T-cells
-
Hanoi, VietnamVinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)
Enrolling by invitation
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Mar 22, 2023
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)
Not yet recruiting
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- (no location specified)
Mar 23, 2023
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,
Not yet recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- +6 more
- Bridging radiation therapy
- +2 more
- (no location specified)
Jan 4, 2023
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)
Not yet recruiting
- Leukemia, Acute Lymphoblastic
- Lymphoma, Non-Hodgkin
- CART-19
-
Ribeirao Preto, Sao Paulo, BrazilRibeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Odronextamab
- +8 more
- (no location specified)
Aug 7, 2023
LY007 for r/r B-NHL and Exploration of Novel CAR-T Translational
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- (no location specified)
Sep 19, 2023
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023
Relapsed or Refractory Mantle Cell Lymphoma (MCL) Trial in Duarte (BAFFR-CAR T cells)
Recruiting
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- BAFFR-CAR T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Oct 18, 2022
T-cell Non-Hodgkin's Lymphoma Trial (CD147- CAR T cells)
Not yet recruiting
- T-cell Non-Hodgkin's Lymphoma
- CD147- CAR T cells
- (no location specified)
Aug 1, 2022
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma Trial in Chicago (Fenretinide)
Not yet recruiting
- T-cell Lymphoma
- +10 more
-
Chicago, IllinoisRush University Medical Center
Oct 24, 2022
CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Suzhou (ThisCART19A with Dose Level 1, ThisCART19A with Dose Level
Recruiting
- CAR
- +2 more
- ThisCART19A with Dose Level 1
- ThisCART19A with Dose Level 2
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jan 18, 2023
Lymphoma, Non-Hodgkin Lymphoma, B-Cell Trial (BAFF CAR-T)
Not yet recruiting
- Lymphoma, Non-Hodgkin Lymphoma, B-Cell
- BAFF CAR-T
- (no location specified)
Aug 16, 2022
Non Hodgkin Lymphoma Trial in Aurora (UCD19 CAR T Cells)
Active, not recruiting
- Non Hodgkin Lymphoma
- UCD19 CAR T Cells
-
Aurora, ColoradoUniversity of Colorado Hospital
Sep 1, 2022
Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),
Not yet recruiting
- Non Hodgkin's Lymphoma
- TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
- +2 more
-
Beijing, China
- +2 more
Aug 23, 2023
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)
Not yet recruiting
- Non Hodgkin Lymphoma
- +5 more
- Pirtobrutinib
- LV20.19 CAR T cells
- (no location specified)
Aug 4, 2023
B Cell Non-Hodgkin's Lymphoma Trial in Duarte (CD19/CD20-directed CAR-T cells)
Recruiting
- B Cell Non-Hodgkin's Lymphoma
- CD19/CD20-directed CAR-T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 10, 2022
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,
Recruiting
- Lymphoma, Non-Hodgkin
- +6 more
- CB-010
- +2 more
-
Scottsdale, Arizona
- +7 more
Aug 19, 2022
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia Trial in Cleveland (Fully human anti CD19 CAR-T
Recruiting
- Non Hodgkin Lymphoma
- +2 more
- Fully human anti CD19 CAR-T Cell Dose
- +2 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Oct 4, 2022
Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Autologous CD19-STAR-T cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2022
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell
Active, not recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +10 more
- Pembrolizumab
- Romidepsin
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023